

1 **Population-weighted seroprevalence from SARS-CoV-2 infection, vaccination, and hybrid**
2 **immunity among U.S. blood donations from January-December 2021**

3

4 Michael P. Busch,^{1,2} Susan L. Stramer,³ Mars Stone,^{1,2} Elaine A. Yu,^{1,2} Eduard Grebe,^{1,2} Edward Notari,³
5 Paula Saa,³ Robyn Ferg,⁴ Irene Molina Manrique,⁴ Natalia Weil,⁴ Rebecca V. Fink,⁴ Matt Levy,⁴ Valerie
6 Green,⁵ Sherri Cyrus,⁵ Phillip C. Williamson,⁵ James Haynes,³ Jamel Groves,³ David Kryzstof,³ Brian
7 Custer,^{1,2} Steve Kleinman,¹ Brad J. Biggerstaff,⁶ Jean D. Opsomer,^{4*} Jefferson M. Jones^{7*}

8

9 * Senior authors contributed equally

10 ¹ Vitalant Research Institute, San Francisco, California, USA

11 ² University of California San Francisco, San Francisco, California, USA

12 ³ American Red Cross, Scientific Affairs, Gaithersburg and Rockville, Maryland, USA

13 ⁴ Westat, Rockville, Maryland, USA

14 ⁵ Creative Testing Solutions, Tempe, Arizona, USA

15 ⁶ Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

16 ⁷ Centers for Disease Control and Prevention, Atlanta, Georgia, USA

17

18 **Corresponding authors**

19 Michael P. Busch, MD. PhD

20 Vitalant Research Institute

21 270 Masonic Avenue

22 San Francisco, CA 94118

23 mbusch@vitalant.org

24 **Running title:** SARS-CoV-2 seroprevalence

1 **ABSTRACT**

2 **Background:** Previous SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) vaccination,
3 independently and combined (“hybrid immunity”), result in partial protection from subsequent infection
4 and strong protection from severe disease. Proportions of the U.S. population that have been infected,
5 vaccinated, or with hybrid immunity remain unclear, posing a challenge for assessing effective pandemic
6 mitigation strategies.

7 **Methods:** In this serial cross-sectional study, nationwide blood donor specimens collected during
8 January–December 2021 were tested for spike and nucleocapsid antibodies, and donor COVID-19
9 vaccination history of ≥ 1 dose was collected. Monthly seroprevalence induced from SARS-CoV-2
10 infection, COVID-19 vaccination, or both, were estimated. Estimates were weighted to account for
11 demographic differences from the general population, and were compared temporally and by
12 demographic factors.

13 **Results:** Overall, 1,123,855 blood samples were assayed. From January to December 2021, the weighted
14 percentage of donations with seropositivity due to: vaccination without previous infection increased from
15 3.5% (95% CI, 3.4%-3.7%) to 64.0%, (95% CI, 63.5%-64.5%); previous infection without vaccination
16 decreased from 15.6% (95% CI, 15.2%-16.0%) to 11.7% (95% CI, 11.4%-12.0%); hybrid immunity
17 increased from 0.7% (95% CI, 0.6%-0.7%) to 18.9% (95% CI, 18.5%-19.3%); and from infection,
18 vaccination, or both increased from 19.8% (95% CI (19.3-20.2) to 94.5% (95% CI, 93.5%-94.0% 0.1%).
19 Infection- and vaccination-induced antibody responses varied significantly by age, race-ethnicity, and
20 region, but not by gender.

21 **Conclusions:** Our results indicate substantial increases in population humoral immunity from SARS-
22 CoV-2 infection, COVID-19 vaccination, and hybrid immunity during 2021. These findings are important
23 to consider in future COVID-19 studies and long-term pandemic mitigation efforts.

24
25 **Key Words:** SARS-CoV-2, seroprevalence, antibodies, vaccination, immunity

1 **Abbreviations:**

2 American Red Cross (ARC)

3 antibodies for SARS-CoV-2 nucleocapsid antibodies (anti-N)

4 antibodies for SARS-CoV-2 spike antibodies (anti-S)

5 Centers for Disease Control and Prevention (CDC)

6 coronavirus disease 2019 (COVID-19)

7 donor history questionnaire (DHQ)

8 Food and Drug Administration (FDA)

9 immunoglobulin (Ig)

10 National Blood Donor Serosurveillance (NBDS)

11 nucleocapsid (NC)

12 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

13 signal-to-cutoff ratio (S/CO)

14 spike (S)

ACCEPTED MANUSCRIPT

1 **BACKGROUND**

2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus
3 disease 2019 (COVID-19), has resulted in over 981,000 deaths and 80.1 million cases in the U.S. as of
4 April 8, 2022 [1]. COVID-19 vaccinations [2], previous SARS-CoV-2 infections [3, 4], and especially
5 hybrid immunity [5, 6] are protective against severe consequences of SARS-CoV-2 infection. Hybrid
6 immunity has been defined as the immunological responses of individuals with histories of both previous
7 SARS-CoV-2 infection and vaccination [5, 6]. Long-term public health prevention strategies remain a
8 substantial challenge due to gaps including the accurate and timely determination of population immunity
9 induced by SARS-CoV-2 infections and COVID-19 vaccinations.

10 There are logical reasons why population immunity against SARS-CoV-2 is difficult to assess. A sizeable
11 proportion of SARS-CoV-2 infections are asymptomatic [7] or result in mild COVID-19 disease [8],
12 which is less likely to be recognized [9]. Characterizing population immunity requires accounting for
13 these un-diagnosed SARS-CoV-2 infections. This is difficult to accurately track with gold standard
14 COVID-19 nucleic acid amplification tests [10] because their utility at the population level is constrained
15 by narrow detection windows dependent on viral kinetics and clearance [11], high cost, and need for
16 specialized laboratory facilities [10]. Many people may not seek diagnostic testing or only use at-home
17 tests without reporting results. As a result, the estimated proportion of the population with infection-
18 induced or hybrid immunity remains unclear. Moreover, national SARS-CoV-2 infection and vaccination
19 data are often collected independently and are therefore difficult to combine into estimates for hybrid
20 immunity.

21 Investigators have estimated seroprevalence via detection of SARS-CoV-2 spike (S) and nucleocapsid (N)
22 protein antibodies [12-14]. Assays that can reliably detect and differentiate SARS-CoV-2 infection and
23 vaccination-induced antibodies are optimal for serosurveillance [15]. Determining proportions of the
24 population with antibodies from vaccination, infection, or both is needed to inform pandemic mitigation
25 efforts.

1 Our study objective was to estimate national trends in the proportions of individuals with previous SARS-
2 CoV-2 infection, COVID-19 vaccination, or both, in 2021, based on seroprevalence of SARS-CoV-2
3 antibodies and self-reported vaccination status among U.S. blood donors. We report population-weighted
4 estimates temporally by calendar month and compare results by demographic factors.

5 **METHODS**

6 *Settings and participants*

7 The present analysis is part of a larger National Blood Donor Seroprevalence (NBDS) Study, which
8 began in July 2020 and is funded by the Centers for Disease Control and Prevention (CDC) [12]. In the
9 NBDS study, donor and donation data were collected in all 50 states, Washington, D.C., and Puerto Rico
10 by 17 participating blood collection organizations, with results compiled in 66 study regions [12].
11 Random or convenience sampling was used to identify and test at least 2,000 blood specimens per month
12 from every region in each blood collection organization's catchment area. When <2000 specimens were
13 available, 100% were sampled. To facilitate comparisons by race and ethnicity, blood donor regions with
14 higher proportions of racial and ethnic minorities were oversampled (4,000 blood samples/month).
15 Detailed methods of this study have previously been published [12].

16 This analysis evaluated the subset of NBDS blood donors with vaccination history. Participants were
17 individuals who donated blood at American Red Cross (ARC) and Vitalant, the two largest blood
18 collection organizations in the U.S., representing 54 of 66 NBDS study regions. Inclusion criteria were
19 having: 1) blood donation between January 1 and December 31, 2021; 2) residence in study regions; 3)
20 satisfaction of U.S. Food and Drug Administration (FDA) regulations and each blood collection
21 organization's donation requirements (e.g., age \geq 16 years, >110 lbs., healthy including being afebrile); 4)
22 measurement of SARS-CoV-2 antibodies; and 5) self-reported COVID-19 vaccination history. Excluded
23 were: 1) persons making COVID-19 convalescent plasma donations; and 2) records missing demographic
24 data.

25

26

1 *Donor demographic and vaccination data*

2 At each visit, donors were asked to provide demographic information (date of birth, gender, race and
3 ethnicity, residential ZIP code) and completed a donor history questionnaire (DHQ) that included a
4 question regarding having ever received a COVID-19 vaccination.

5 *Laboratory assays for SARS-CoV-2 antibodies*

6 All blood specimens were assayed for antibodies for SARS-CoV-2 spike glycoprotein (anti-S; VITROS
7 chemiluminescent S1 total Ig assay; Ortho Clinical Diagnostics). Prior to August 31, 2021, only
8 specimens that were anti-S seropositive were subsequently tested for antibody to SARS-CoV-2 N protein
9 (anti-N; Roche Elecsys Total Ig Assay; Roche Diagnostics). From September 2021, donations were tested
10 in parallel for anti-S and anti-N (VITROS chemiluminescent total Ig assays; Ortho Clinical Diagnostics);
11 previous studies found that the impact of this algorithm would be minimal since 99% of specimens with
12 anti-N antibodies have anti-S antibodies [16]. We previously validated these assays for sensitivity,
13 specificity, and durability of detection of anti-S and anti-N antibodies following infection [16]. Testing of
14 ARC and Vitalant donation specimens for the NBDS program was performed at five laboratories operated
15 by Creative Testing Solutions. Seropositivity was defined as signal-to-cutoff ratio (S/CO) ≥ 1.0 , per
16 manufacturers' instructions.

17 *Primary outcomes*

18 We defined SARS-CoV-2 infection and COVID-19 vaccination status based on serologic assays for
19 SARS-CoV-2 antibodies and self-reported COVID-19 vaccination history at each donation. SARS-CoV-2
20 infection was defined as seropositivity for anti-N or, in the absence of reported vaccination, for anti-S.
21 Combined SARS-CoV-2 seropositivity was defined as having any of previous SARS-CoV-2 infection,
22 COVID-19 vaccination, or both (the latter also called “hybrid immunity;” *eTable 1*).

23 *Statistical analyses*

24 We used a complete-case analysis approach for observations without missing data (*Figure 1*). A small
25 percentage (0.8%) of samples were excluded due to missing race or ethnicity information. Among a small
26 number of observations with seropositivity for anti-S and missing values for anti-N (N=5,034; <0.5%),

1 we imputed anti-N seropositivity based on data from all participants with anti-N values and matching
2 anti-S values (*eMethods*).

3 We used weights to adjust for demographic differences between blood donors in our study data and the
4 population aged ≥ 16 years in blood donor catchment regions. All reported values are weighted unless
5 stated otherwise. Details of the weighting methodology have been previously published [12] and are
6 described in the *eMethods*. In brief, weights were calculated by calibrating (via raking and trimming) the
7 final analytic subset to representative demographic data from the U.S. Census Bureau in blood donor
8 catchment regions [17]. Specifically, the following variables and data from the 2014-2018 American
9 Community Survey were utilized: age categories (16-24, 25-34, 35-44, 55-64, ≥ 65 years), biological sex,
10 race and ethnicity (self-identified from 7 fixed categories), and geographic location [17]. Variance
11 estimates (standard errors for confidence limits) were calculated using 50 replicate weights constructed by
12 jackknife repeated replication, a resampling technique [18].

13 In each month's cross-sectional data, we generated population-weighted percentages and 95% CIs of
14 seropositivity from previous SARS-CoV-2 infection and from COVID-19 vaccination (*eMethods*). We
15 evaluated relative levels of antibody to S by calculating means (SDs) and medians (IQRs) of anti-S
16 intensity ($\log_{10} S/CO$) on the VITROS S1 Total Ig assay. For geographic comparisons, we combined
17 donor ZIP codes into nine Census divisions (*eFigure 1*). Statistical analysis was conducted with SAS
18 (version 9.4; SAS Institute; Cary, North Carolina, U.S.).

19 *Comparisons between vaccination coverage estimates*

20 We compared our estimated rate of vaccination in blood donors with the expected vaccination coverage
21 derived from CDC data. We first identified 54 study regions across 31 states with available CDC
22 vaccination data. To ensure that the same geographic areas were represented each month, sampled
23 geographic regions from each blood collection organization were defined by ZIP codes where more than
24 90% of blood donors resided. Specimens from donors residing outside those ZIP codes were excluded
25 (*eMethods*). From these aggregated ZIP codes, study regions were created based on state and
26 metropolitan borders. CDC data specifically include daily numbers of people and percentages of adults

1 (aged ≥ 18 years of age) in each county who received \geq one vaccine dose. Among study participants who
2 donated in the study regions, we compared two versions of our weighted monthly vaccination estimates
3 based on: 1) self-reported COVID-19 vaccination; and 2) self-reported COVID-19 vaccination with
4 serologic confirmation (seropositivity for anti-S). Further details are described in the *eMethods*.

5 *Ethics*

6 The study protocol was approved by the University of California, San Francisco, ARC, and Westat
7 Institutional Review Boards. All donors provided voluntary, informed consent for use of their
8 deidentified data and residual blood samples from routine blood donations for research. This study was
9 deemed non-human subjects' research. This activity was reviewed by CDC and was conducted consistent
10 with applicable federal law and CDC policy (e.g., 45 C.F.R. part 46; 21 C.F.R. part 56; 42 U.S.C. 241(d),
11 5 U.S.C. 552a, 44 U.S.C. 3501). We report study methodology according to the Strengthening the
12 Reporting of Observational Studies in Epidemiology guidelines for cross-sectional studies [19].

13 **RESULTS**

14 This study included 1,123,855 blood donations collected from January 1 to December 31, 2021, across
15 the U.S. (*eFigure 1, Table 1*). The number of donations included per month ranged between 92,096 and
16 97,170 (*eTable 2*). Overall, study donors had a mean age of 51.4 years; 51.2% were female, 87.9% were
17 non-Hispanic White, 2.5% were non-Hispanic Black, and 5.6% were Hispanic, based on unweighted
18 values (*Table 1*). Demographic comparisons of study blood donors with the general population, in study
19 regions and nationally, are in *Table 1*; race-ethnicity differed between the study sample and national
20 Census data.

21 From January to December 2021, the weighted monthly percentage of donations with seropositivity due
22 to: (1) vaccination without previous infection increased from 3.5% (95% CI, 3.4%-3.7%) to 64.0%, (95%
23 CI, 63.5%-64.5%), (2) previous infection without vaccination decreased from 15.6% (95% CI, 15.2%-
24 16.0%) to 11.7% (95% CI, 11.4%-12.0%), and (3) hybrid immunity increased from 0.7% (95% CI, 0.6%-
25 0.7%) to 18.9% (95% CI, 18.5%-19.3%; *Figure 2A, eTable 2*). Combined seroprevalence from previous
26 infection, vaccination, or both, increased from 19.8% to 94.5% (*eTable 2*).

1 By December, estimated population vaccination coverages were: 83.0% (95% CI, 82.6%-83.4%) from
2 donor self-report, and 82.9% (95% CI, 82.5%-83.3%) from donor self-report with anti-S antibody
3 confirmation (**Figure 2B, eTable 2**). These estimates were similar to the CDC-data-derived estimate [20],
4 which was 81.3% as of December 31, 2021. In January 2021, the vaccination coverage extrapolated from
5 blood donors was higher than CDC vaccination estimates; differences declined during the last quarter of
6 2021. Among donations from donors who self-reported vaccination in the DHQ, 97.4% had anti-S
7 antibody during 2021, and >99% had anti-S antibody between June and December 2021 (**eTable 2**).

8 Monthly estimates of the percentage of individuals with infection- and vaccination-induced antibody
9 responses varied by age (**Figure 3**), race and ethnicity (**Figure 4**), and region (**Figure 5**), but not by
10 gender (**eFigure 2**). Estimated seroprevalence from vaccination was positively associated with age: the
11 percentage among older individuals (aged ≥ 65 years) was highest during all months except January
12 (**Figure 3, eTable 3**). In December, estimated seroprevalence from vaccination was 89.0% (95% CI,
13 88.4%-89.7%) among individuals ≥ 65 years, 85.6% (95% CI, 85.1%-86.1%) among individuals 50-64
14 years, 82.7% (95% CI, 82.0%-83.4%) among individuals 30-49 years, and 75.2% (95% CI, 74.1%-
15 76.3%) among individuals 16-29 years. Estimated seroprevalence from previous infection was inversely
16 associated with age group; across all timepoints, individuals between 16-29-years had the highest
17 prevalence and those ≥ 65 years had the lowest prevalence. Estimated seroprevalence from hybrid
18 immunity was similar among age groups from January to July, and inversely associated with age during
19 the remaining months. By December, estimated seroprevalence from hybrid immunity was 24.0% (95%
20 CI, 22.7%-25.2%) among individuals 16-29 years and 12.5% (95% CI, 11.8%-13.1%) among individuals
21 ≥ 65 years.

22 In December, estimated seroprevalence from infection was 40.0% (95% CI, 38.0%-41.9%) among
23 Hispanic people, 34.8% (95% CI, 33.0%-36.6%) among Black (non-Hispanic) people, 28.7% (95% CI,
24 28.3%-29.2% among White (non-Hispanic) people and 22.3% (95% CI, 20.0%-24.5%) among Asian
25 people (**Figure 4; eTable 3**). Estimated seroprevalence from hybrid immunity was 26.5% (95% CI,
26 24.8%-28.3%) among Hispanic people, 20.7% (95% CI, 19.0%-22.6%) among Black (non-Hispanic)

1 people, 17.3% (95% CI, 16.9%-17.7%) among White (non-Hispanic) people, 16.3% (95% CI, 13.9%-
2 19.2%) among people categorized as Other race and ethnicity, and 15.4% (95% CI, 13.5%-17.6%) among
3 Asian people.

4 Comparing by Census divisions, estimated seroprevalence from vaccination was similar during the first
5 quarter of 2021 (*Figure 5, eTable 3*). Estimated seroprevalence from infection was lower in the New
6 England and Pacific Census divisions during most months, whereas seroprevalence from infection was
7 highest in the East South Central, West South Central and Mountain divisions. For example, in the New
8 England division estimated seroprevalence from infection increased from 9.9% (95% CI, 8.7%-11.3%) to
9 20.0% (95% CI, 18.7%-21.4%) over the year, whereas in the East South-Central Division seroprevalence
10 increased from 22.7% (95% CI, 21.1%-24.3%) to 40.2% (95% CI, 38.6%-41.8%).

11 Mean log anti-S S/CO values were highest among donors with seropositivity from hybrid immunity,
12 followed by that among those with vaccination (without previous infection), and lowest among those with
13 previous infection but no vaccination (*Figure 6A*). These differences were significant throughout the
14 year. There was a transient decline in anti-S antibody levels from August through November. Although
15 the mean levels of anti-S were consistently highest among those with hybrid immunity compared to those
16 with vaccination-induced or infection-induced immunity, there was substantial overlap in the distribution
17 of antibody levels among these subgroups (*Figure 6B*).

18 **DISCUSSION**

19 Our findings demonstrate that U.S. population-weighted, estimated seroprevalence from SARS-CoV-2
20 infection, vaccination, or both, increased from 19.8% in January 2021 to 94.5% in December 2021. This
21 study is the first to report national estimates of the proportion of the population with hybrid immunity,
22 which reached 18.9% by December 2021.

23 We found the proportion of adult blood donors reporting at least 1 dose of vaccine was approximately
24 80% by December, similar to CDC vaccination-data-derived estimates. Infection-induced seroprevalence
25 estimates derived from blood donors are similar to seroprevalence estimates among adults reported by a
26 nationwide seroprevalence study using commercial laboratory remnants [1]. This suggests that although

1 blood donors differ from the general population, our donor-derived and weighted seroprevalence
2 estimates might be representative of the adult U.S. population. From June through December 2021, >99%
3 of donors with self-reported vaccination had anti-S antibodies. This suggests that nearly all healthy
4 individuals who qualified as blood donors seroconverted after vaccination; this finding is consistent with
5 findings from vaccine clinical trials and observational studies in immunocompetent populations [21, 22].
6 The proportions of infection-induced, vaccination-induced, and infection-and-vaccine-induced
7 seroprevalence differed by age, racial-ethnic subgroup, and geographic region. These observations are
8 consistent with prior studies demonstrating differential vaccination coverage and SARS-CoV-2 infections
9 among demographic subgroups [23-27]. Because demographic subgroups with higher estimated vaccine-
10 induced seroprevalence had lower estimated infection-induced seroprevalence, demographic differences
11 in the combined seroprevalence from vaccination, infection, or both, were generally small. We note that
12 some observed temporal patterns coincided with the delta variant surge and vaccination rollout in the U.S.
13 For example, the proportion of younger unvaccinated individuals (16-29 years) with seropositivity from
14 previous infection increased during the last quarter of 2021; incident infections from the delta variant are
15 a likely explanation, as reported cases were higher among younger than older adults during the delta
16 surge [1]. Increased proportions of infection among younger adults are potentially related to lower
17 vaccination rates prior to the delta surge.

18 We estimated that nearly one in five individuals had hybrid immunity, based on vaccination history and
19 serologic evidence of previous infection, by the end of 2021. People with hybrid immunity have been
20 reported to possess more robust immune responses [28], and increased protection from infection and
21 severe disease [29], compared to persons with either vaccination or previous infection alone [6, 30].
22 However, rapid waning of neutralizing antibody and IgG antibody to the S protein has been reported [31].
23 Studies in the U.S. and other countries demonstrate substantial numbers of infections in vaccinated
24 persons, and of reinfections, associated with variants of concern, particularly omicron [32-39].
25 Given the high seroprevalence among NBDS donors and the limitations of the cross-sectional study
26 design, monthly serosurveillance was discontinued in December 2021 after 18 months of data collection.

1 In the next study phase, we have established a longitudinal cohort study comprised of approximately
2 142,000 repeat blood donors in the ARC and Vitalant blood collection networks throughout the
3 continental U.S. SARS-CoV-2 binding antibody assays, including anti-S (IgG; quantitative), anti-N (total
4 Ig) and neutralizing antibody assays, will be performed on serially collected blood specimens donated
5 between July 2020 and December 2022. Donor survey questionnaires will capture detailed histories of
6 COVID-19 vaccination, diagnostic testing, and clinical outcomes. Key study objectives include
7 determining: 1) stability and waning of anti-S, anti-N and neutralizing antibody among donors who were
8 previously infected, vaccinated, or both, 2) rates of reinfection and of infections in vaccinated persons;
9 and 3) vaccine effectiveness and serologic correlates of protection against omicron and future variants.
10 This study has several limitations. First, seroprevalence among blood donors might not represent the
11 seroprevalence in the general population. Second, vaccination history was self-reported at the time of
12 each donation and did not include vaccination details (brands/types, number of doses, dates received).
13 Third, given the monthly cross-sectional study design of the NBDS, we were unable to determine if those
14 with hybrid immunity had been infected first and subsequently vaccinated, or vice versa, nor could we
15 determine the precise timing of infection and vaccination. Fourth, anti-S reactive, anti-N nonreactive
16 donors might have incorrectly reported no previous COVID-19 vaccination and have been misclassified
17 as infected. Fifth, the antibody assays used in this study are authorized from the FDA for use as
18 qualitative assays and quantitative results should be interpreted with caution. However, a strength of the
19 current study is that the antibody assays used are optimal for serosurveillance because they maintain
20 reactivity for more than a year following infection or vaccination, allowing ascertainment of cumulative
21 infection or vaccination-induced humoral immune responses [16, 27].
22 From evaluation of over 1.1 million blood samples, our donor-derived and population-weighted estimates
23 of seroprevalence demonstrate increases in population humoral immunity due to SARS-CoV-2 infection,
24 COVID-19 vaccination, or both during 2021. Percentages of estimated seroprevalence differed by age,
25 race-ethnicity, and geographic region. Seroprevalence studies in representative big datasets like this one,
26 with additional details that can be stratified based on number of vaccination doses and timing of each

1 vaccine dose are important to consider in future COVID-19 studies and long-term pandemic mitigation
2 efforts, particularly in the context of antibody waning, booster vaccination schedules, and emergent
3 SARS-CoV-2 variants.

4 **NOTES**

5 **Acknowledgments**

6 The authors would like to acknowledge the Nationwide Blood Donor Seroprevalence study team (below)
7 and staff at CDC, VRI, Westat, the American Red Cross, participating blood collection organizations and
8 testing laboratories, and blood donors whose samples were analyzed in this study.

9 The present analysis is part of a larger National Blood Donor Seroprevalence (NBDS) Study, which
10 began in July 2020. This analysis evaluated the subset of blood donors with vaccination history. Results
11 of the larger study that did not incorporate vaccine history have been previously published, including in
12 a manuscript for results through May 2021 (ref. 12 Jones JM, Stone M, Sulaeman H, et al. Estimated US
13 Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May
14 2021. *JAMA* 2021; 326(14): 1400-9) and results through December 2021 on a CDC website
15 (<https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence>).

16 The Nationwide Blood Donor Seroprevalence Study is the responsibility of the following persons:

17 Centers for Disease Control and Prevention

18 J.M. Jones, M. Miller, B. Biggerstaff, T. Benoit and N. Thornburg, Atlanta, GA

19 Vitalant Research Institute

20 M.P. Busch and M. Stone, San Francisco, CA

21 Westat

22 S.M. Mathew, J.D. Opsomer, and R.V. Fink, Rockville, MD

23 Blood Collection Organizations (BCOs)

24 American Red Cross, Gaithersburg, MD, S. L. Stramer, E. Notari, and P. Saa

25 Banco de Sangre de Servicios Mutuos, San Juan, PR, G. Latoni

26 Blood Bank of Alaska, Anchorage, M. Ritter

27 Blood Bank of Hawaii, Honolulu, HI, K. Nguyen

28 Blood Works Northwest, Seattle, WA, M. Destree

1 Carter BloodCare, Bedford, TX, M. Sayers
2 Gulf Coast Regional Blood Center, Houston, Texas, S. Rossman
3 LifeServe, Des Moines, Iowa, S. Sime
4 LifeSouth Community Blood Centers, Gainesville, Florida, C. Lough
5 New York Blood Center Enterprise, New York, NY, D. Strauss and D. Kessler
6 OneBlood, St. Petersburg, FL, R Reik and C. Engert
7 The Blood Center, New Orleans, Louisiana, B. Weales
8 Vitalant, San Francisco, CA and Scottsdale, AZ, B. Custer and R. Vassallo
9 Versiti, Milwaukee, Wisconsin, D. Bougie and A. Mast

10 Testing Laboratories

11 Creative Testing Solutions, Temple, AZ, P. Williamson, S. Cyrus, and V. Green
12 Innovative Blood Resources, St Paul, Minnesota, J. Gorlin
13 Gulf Coast Regional Blood Center, Houston, Texas, S. Rossman
14 Rhode Island Blood Center, Providence, RI, J. Alberigo and D. Strauss
15 The Blood Center, New Orleans, Louisiana, B. Weales and R. Chatelain
16 Vitalant Research Institute, San Francisco, CA, C. Di Germanio and G. Simmons

17 Consultant

18 S. Kleinman, University of British Columbia, Victoria, British Columbia, Canada

19 **Disclaimer**

20 The findings and conclusions in this report are those of the authors and do not necessarily represent the
21 official position of the Centers for Disease Control and Prevention.

22 **Funding**

23 This study was supported by a research contract from the Centers for Disease Control and Prevention
24 (CDC Contract 75D30120C08170).

25 **Conflict of interest**

26 MPB reports being an employee of Vitalant Research Institute and receiving grant funding for their
27 institution. EG reports research funding to their employer Vitalant Research Institute from Ortho Clinical
28 Diagnostics. They also report the provision of reagents for other studies from Ortho Clinical Diagnostics
29 and Roche.

30 SK, SS, DK, IMM, JH, PCW, SC, BC, JG, JMJ, JO, ML, MS, PS, RF, RVF, VG, BJB, EAY, and EN
31 report no conflicts on interest.

32
33

References

1. Centers for Disease Control and Prevention. CDC COVID Data Tracker: Trends in cases and deaths by race/ethnicity, age, and sex. Available at: <https://covid.cdc.gov/covid-data-tracker/#demographicsovertime>. Accessed April 6.
2. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. *Nature Reviews Immunology* **2021**; 21(10): 626-36.
3. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. *The Lancet Infectious Diseases* **2022**; 22(1): 12-4.
4. Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. *New England Journal of Medicine* **2022**.
5. Crotty S. Hybrid immunity. *Science* **2021**; 372(6549): 1392-3.
6. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. *Science Immunology* **2022**; 7(68): eabn8014.
7. Ma Q, Liu J, Liu Q, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. *JAMA Network Open* **2021**; 4(12): e2137257-e.
8. Gao W, Lv J, Pang Y, Li L-M. Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic. *BMJ* **2021**; 375: n2342.
9. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Network Open* **2021**; 4(1): e2035057-e.
10. Kevadiya BD, Machhi J, Herskovitz J, et al. Diagnostics for SARS-CoV-2 infections. *Nature Materials* **2021**; 20(5): 593-605.
11. Néant N, Lingas G, Le Hingrat Q, et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. *Proceedings of the National Academy of Sciences* **2021**; 118(8): e2017962118.
12. Jones JM, Stone M, Sulaeman H, et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. *JAMA* **2021**; 326(14): 1400-9.
13. Stadlbauer D, Tan J, Jiang K, et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. *Nature* **2021**; 590(7844): 146-50.
14. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA Network Open* **2021**; 4(1): e2033706-e.
15. Alejo JL, Mitchell J, Chang A, et al. Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19. *JAMA* **2022**.
16. Stone M, Grebe E, Sulaeman H, et al. Evaluation of commercially available high-throughput SARS-CoV-2 serological assays for serosurveillance and related applications. *Emerg Infect Dis* **2022**; 28(3): 672-83.
17. U.S. Census Bureau. American Community Survey data. <https://www.census.gov/programs-surveys/acs/data.html>.
18. Rust KF, Rao JN. Variance estimation for complex surveys using replication techniques. *Stat Methods Med Res* **1996**; 5(3): 283-310.
19. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* **2014**; 12(12): 1500-24.
20. Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. Available at: <https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Jurisdi/uns-k-b7fc>. Accessed April 6.

- 1 21. Ward H, Whitaker M, Flower B, et al. Population antibody responses following COVID-19
2 vaccination in 212,102 individuals. *Nature Communications* **2022**; 13(1): 907.
- 3 22. Dodd RY, Notari EP, Brodsky JP, et al. Patterns of Antibody Response to Severe Acute
4 Respiratory Syndrome Coronavirus 2 Among 1.6 Million Blood Donors: Impact of Vaccination,
5 United States, December 2020–June 2021. *The Journal of Infectious Diseases* **2022**; 225(1): 5-9.
- 6 23. Nguyen LH, Joshi AD, Drew DA, et al. Self-reported COVID-19 vaccine hesitancy and uptake
7 among participants from different racial and ethnic groups in the United States and United
8 Kingdom. *Nature Communications* **2022**; 13(1): 636.
- 9 24. Ferguson JM, Justice AC, Osborne TF, Magid HSA, Purnell AL, Rentsch CT. Geographic and
10 temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between February
11 2020 and August 2021 in the United States. *Scientific Reports* **2022**; 12(1): 273.
- 12 25. Martin B, DeWitt PE, Russell S, et al. Characteristics, Outcomes, and Severity Risk Factors
13 Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort
14 Collaborative. *JAMA Network Open* **2022**; 5(2): e2143151-e.
- 15 26. Wilkinson NM, Chen H-C, Lechner MG, Su MA. Sex Differences in Immunity. *Annual Review*
16 *of Immunology* **2022**; 40(1): null.
- 17 27. Dodd RY, Spencer BR, Xu M, et al. Characteristics of US Blood Donors Testing Reactive for
18 Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines. *Transfus Med Rev*
19 **2021**; 35(3): 1-7.
- 20 28. Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing
21 antibodies elicited by SARS-CoV-2 infection. *Science* **2021**.
- 22 29. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19
23 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population
24 cohort study in Sweden. *The Lancet Infectious Diseases* **2022**.
- 25 30. Andreano E, Paciello I, Piccini G, et al. Hybrid immunity improves B cells and antibodies against
26 SARS-CoV-2 variants. *Nature* **2021**; 600(7889): 530-5.
- 27 31. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses
28 and duration of immunity: a longitudinal study. *The Lancet Microbe* **2021**; 2(6): e240-e9.
- 29 32. Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough
30 infections in vaccinated individuals: measurement, causes and impact. *Nature Reviews*
31 *Immunology* **2022**; 22(1): 57-65.
- 32 33. Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-CoV-2
33 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nature Medicine* **2021**; 27(8):
34 1379-84.
- 35 34. Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2
36 breakthrough infections after vaccination and booster with BNT162b2. *Nature Medicine* **2021**;
37 27(12): 2108-10.
- 38 35. Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine breakthrough COVID-19
39 infections. *The Lancet Infectious Diseases* **2021**; 21(11): 1485-6.
- 40 36. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection
41 With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. *JAMA* **2021**;
42 326(19): 1930-9.
- 43 37. Gupta RK, Topol EJ. COVID-19 vaccine breakthrough infections. *Science* **2021**; 374(6575):
44 1561-2.
- 45 38. Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron
46 despite mRNA vaccine booster dose. *The Lancet* **2022**; 399(10325): 625-6.
- 47 39. Prete CA, Buss LF, Buccheri R, et al. Reinfection by the SARS-CoV-2 Gamma variant in blood
48 donors in Manaus, Brazil. *BMC Infectious Diseases* **2022**; 22(1): 127.

1 **FIGURE LEGENDS**

2 **Figure 1: Flowchart of blood samples from American Red Cross and Vitalant donors**

3 ^aExcluding blood samples from Chicago, Northern New Jersey, and Pittsburgh Vitalant sites due to no available self-reported vaccination history.
4 Abbreviations: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

5
6 **Figure 2:** Previous SARS-CoV-2 infection was defined as seropositivity for anti-N or, in the absence of
7 reported vaccination, for anti-S. Vaccination was defined at as self-report of ≥ 1 COVID-19 vaccine dose
8 on the donor history questionnaire (eTable 1). Estimated vaccination coverage from CDC data was
9 defined as ≥ 1 COVID-19 vaccine dose among residents aged ≥ 18 years in counties in the catchment area
10 of the study (eFigure 1).

11 Abbreviations: American Red Cross (ARC), Centers for Disease Control and Prevention (CDC), coronavirus disease 2019 (COVID-19), donor
12 history questionnaire (DHQ), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

13
14 **Figure 3: Population-weighted percentages (95% CIs) of seropositivity by previous SARS-CoV-2**
15 **infection and COVID-19 vaccination status, stratified by age subgroups.** Previous SARS-CoV-2
16 infection was defined as seropositivity for anti-N or, in the absence of reported vaccination, for anti-S.
17 Vaccination was defined at as self-report of ≥ 1 COVID-19 vaccine dose on the donor history
18 questionnaire (eTable 1).

19 Abbreviations: coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

20
21 **Figure 4: Population-weighted percentages (95% CIs) of seropositivity by previous SARS-CoV-2**
22 **infection and COVID-19 vaccination status, stratified by race and ethnicity.** Previous SARS-CoV-2
23 infection was defined as seropositivity for anti-N or, in the absence of reported vaccination, for anti-S.
24 Vaccination was defined at as self-report of ≥ 1 COVID-19 vaccine dose on the donor history
25 questionnaire (eTable 1).

26 Abbreviations: coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), non-Hispanic (NH).

27
28 **Figure 5: Population-weighted percentages (95% CIs) of seropositivity by previous SARS-CoV-2**
29 **infection and COVID-19 vaccination status, stratified by geographic location.** Previous SARS-CoV-2
30 infection was defined as seropositivity for anti-N or, in the absence of reported vaccination, for anti-S.
31 Vaccination was defined at as self-report of ≥ 1 COVID-19 vaccine dose on the donor history
32 questionnaire (eTable 1).

33 Abbreviations: coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

34
35
36 **Figure 6: Population-weighted mean and distribution of SARS-CoV-2 spike protein antibody**
37 **(S/CO), stratified by month and previous SARS-CoV-2 infection and COVID-19 vaccination**
38 **status).** Previous SARS-CoV-2 infection was defined as seropositivity for anti-N or, in the absence of
39 reported vaccination, for anti-S. Vaccination was defined as self-report of ≥ 1 COVID-19 vaccine dose on
40 the donor history questionnaire (eTable 1). **Fig 5A:** Weighted, log-normalized mean and standard
41 deviation values of anti-S antibodies (S/CO values) were reported among blood samples from donations
42 in each calendar month of 2021, stratified by previous infection and vaccination status subgroups. **Fig 5B:**
43 Weighted, log-normalized median and interquartile ranges (25th, 75th percentile) values of weighted anti-S
44 S/CO values were reported, stratified by month, previous infection and vaccination subgroup status of
45 blood donors.

46 Abbreviations: coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), signal-to-cutoff ratio
47 (S/CO), Centers for Disease Control and Prevention (CDC), spike protein (S)

1


Table 1: Demographic characteristics

January - December 2021	Selected sample with vaccination data (ARC and Vitalant)		U.S. Population aged \geq 16 years, in ARC and Vitalant study regions		U.S. Population aged \geq 16 years ^a	
	N	%	N	%	N	%
Total	1,123,855	100%	144,161,836	100%	260,534,061	100%
Male	548,541	49%	70,204,212	49%	126,998,469	49%
Female	575,314	51%	73,957,624	51%	133,535,592	51%
Age (years) ^b						
16 to 29	130,352	12%	34,882,830	24%	62,732,069	12%
30 to 49	327,868	29%	47,186,683	33%	84,217,499	29%
50 to 64	407,597	36%	35,244,590	24%	63,705,642	36%
65+	258,038	23%	26,847,733	19%	49,878,851	23%
Race and ethnicity						
White, non-Hispanic	987,660	88%	92,913,479	64%	164,254,508	63%
Black, non-Hispanic	28,066	2%	17,505,250	12%	30,855,020	12%
Hispanic	62,417	6%	21,213,139	15%	43,854,340	17%
Asian, non-Hispanic	27,332	2%	8,434,430	6%	14,295,323	5%
Other	18,380	2%	4,095,538	3%	7,274,870	3%
Census Division						
1 New England	113,637	10%	10,558,443	7%	12,163,848	5%
2 Middle Atlantic	78,115	7%	15,879,225	11%	33,526,678	13%
3 East North Central	111,607	10%	11,937,628	8%	37,478,378	14%
4 West North Central	121,484	11%	12,221,003	8%	16,752,533	6%
5 South Atlantic	188,133	17%	29,061,803	20%	51,532,352	20%
6 East South Central	84,581	8%	8,588,941	6%	15,109,636	6%
7 West South Central	41,437	4%	8,419,508	6%	30,499,604	12%
8 Mountain	260,402	23%	22,432,600	16%	18,707,146	7%
9 Pacific	124,459	11%	25,062,685	17%	41,984,697	16%

^a Donations from Puerto Rico are included in the total but excluded from Census division strata since Puerto Rico is not included in any Census division.

Abbreviations: American Red Cross (ARC)

2
3
4
5



*Excluding blood samples from Chicago, Northern New Jersey, and Pittsburgh due to no available self-reported vaccination history.
 *All samples had gender, age, residential location, SARS-CoV-2 antibody, and vaccination history data.

Figure 1
 50x39 mm (.17 x DPI)

1
 2
 3
 4
 5
 6
 7
 8




Figure 2
 84x56 mm (.17 x DPI)

9
 10
 11
 12




Figure 3
165x146 mm (.17 x DPI)

1
2
3
4




Figure 4
165x146 mm (.17 x DPI)

1
2
3
4




Figure 5
165x147 mm (.17 x DPI)

1
2
3
4

1
2
3




Figure 6
82x55 mm (.17 x DPI)

ACCEPTED MANUSCRIPT